Administering chemo ups income for non-salaried oncologists

Administering chemo ups income for non-salaried oncologists
Non-salaried oncologists report the potential for increased salaries with the administration of chemotherapy or growth factors for lung or colorectal cancer patients, according to a study published online Dec. 26 in the Journal of Clinical Oncology.

(HealthDay)—Non-salaried oncologists report the potential for increased salaries with the administration of chemotherapy or growth factors for lung or colorectal cancer patients, according to a study published online Dec. 26 in the Journal of Clinical Oncology.

Jennifer L. Malin, M.D., Ph.D., from the University of California at Los Angeles, and colleagues surveyed 480 U.S. oncologists involved in the care of a population-based cohort of patients with lung or colorectal cancer. The authors sought to measure the effects of prescribing chemotherapy or or making referrals to other cancer specialists, hospice, or on medical oncologists' income.

According to the researchers, most oncologists reported that their incomes would be unaffected. But, physicians in fee-for-service practice and those paid a salary with productivity incentives were significantly more likely to report that their income would increase from administering chemotherapy (odds ratios, 7.05 and 7.52, respectively) or administering growth factors (odds ratios, 5.60 and 6.03, respectively), compared with salaried oncologists.

"A substantial proportion of oncologists who are not paid a fixed salary report that their incomes increase when they administer chemotherapy and growth factors," the authors write.

One author disclosed to the pharmaceutical and health insurance industries.

More information: Abstract
Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)

add to favorites email to friend print save as pdf

Related Stories

Few physicians refer patients to cancer clinical trials

Feb 12, 2011

A small proportion of adult cancer patients participate in clinical trials in part due to a low level of physician referrals, according to an online study published Feb. 11 in The Journal of the National Cancer Institute.

Financial hardship common among colon cancer patients

Mar 13, 2012

(HealthDay) -- Nearly 40 percent of patients undergoing adjuvant chemotherapy for stage III colon cancer experience financial hardship, even if they have health insurance coverage, according to research published ...

Recommended for you

Endogenous hormones improve breast cancer risk models

7 hours ago

(HealthDay)—Inclusion of endogenous hormones in prediction models improves prediction of invasive breast cancer risk in postmenopausal women, according to a study published online Aug. 18 in the Journal of ...

Novel oncogenic RET mutation found in small cell lung cancer

8 hours ago

For the first time an oncogenic somatic mutation at amino acid 918 in the RET (rearranged during transfection) protein has been identified in small cell lung cancer (SCLC) tumors and enforced expression of this mutation within ...

User comments